First choice for contemporary depression Review article
Article Sidebar
Main Article Content
Abstract
Although the relationship between the stress and depression is neither obvious, nor fully determined, many authors emphasize the influence of modern lifestyle and contemporary civilization on a new picture of depression and other, emerging depression-like disorders. With regard to this “civilization syndrome”, there are several new psychopathological candidates waiting for psychiatric research, like burnout syndrome and chronic fatigue syndrome, or even so general entities like infertility and solitude. All these phenomena seem to increase epidemically and require adequate therapeutic approach.
During the last two decades, SSRIs became the mainstay of antidepressive and anxiolytic treatment. Actually, SSRIs were the first lifestyle class of antidepressants, focused on the civilization syndrome. After years of the competition between various antidepressants, escitalopram, became the most prominent, first-line antidepressant, because of the combination of its efficacy and tolerance. Many trials comparing escitalopram against other compounds proved its favoring potential both in the acute and long-term treatment effects in major depression and new form of depression-like disorders.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Łoza B., Parnowski T. (red.): Nowa depresja. Nowe leczenie. Medical Education, Warszawa 2013. Wydanie II zmienione.
3. Björntorp P.: Visceral obesity: a “civilization syndrome”. Obes. Res. 1993; 1(3): 206-222.
4. Simon K.: Civilization stress, cardiovascular risk, evidence-based medicine, guidelines. Orv. Hetil. 2009; 150(19): 895-902.
5. Chrysopoulos P.: OECD: Greeks are Hardest Working People in Europe [online; wersja: 29.07.2015].
6. NIK.
7. Maske U.E., Riedel-Heller S.G., Seiffert I. et al.: Prevalence and Comorbidity of Self-Reported Diagnosis of Burnout Syndrome in the General Population. Psychiatr. Prax. 22.07.2015.
8. Cipriani A., Furukawa T.A., Salanti G. et al.: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-758.
9. Cipriani A., Santilli C., Furukawa T.A. et al.: Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst. Rev. 2009, Issue 2.
10. Moore N., Verdoux H., Fantino B.: Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int. Clin. Psychopharmacol. 2005; 20(3): 131-137.
11. Boulenger J.P., Huusom A.K., Florea I. et al.: A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr. Med. Res. Opin. 2006; 22(7): 1331-1341.
12. Ventura D., Armstrong E.P., Skrepnek G.H., Haim Erder M.: Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr. Med. Res. Opin. 2007; 23(2): 245-250.
13. Leonard B., Taylor D.: Escitalopram – translating molecular properties into clinical benefit: reviewing the evidence in major depression. J. Psychopharmacol. 2010; 24: 1143-1152.
14. Lam R.W., Andersen H.F., Wade A.G.: Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials. Int. Clin. Psychopharmacol. 2008; 23(4): 181-187.
15. Bielski R.J., Ventura D., Chang C.C.: A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J. Clin. Psychiatry 2004; 65(9): 1190-1196.
16. Pae C.U., Masand P.S., Peindl K. et al.: An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features. Prim. Care Companion J. Clin. Psych. 2008; 10: 205-210.
17. Łoza B.: Escitalopram: odkrycie leku i jego rozwój. Neuropsychiatria 2011; 3(1): 5-12.
18. Doghramji K.: Treatment strategies for sleep disturbance in patients with depression. J. Clin. Psychiatry 2003; 64(supl. 14): 24-29.
19. Amsterdam J.D., Shults J., Rutherford N.: Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008; 32(1): 100-106.
20. Fonseca M., Soares J.C., Hatch J.P. et al.: An open trial of adjunctive escitalopram in bipolar depression. J. Clin. Psychiatry 2006; 67: 81-86.
21. Bostwick J.M.: A Generalist’s Guide to Treating Patients With Depression With an Emphasis on Using Side Effects to Tailor Antidepressant Therapy. Mayo Clin. Proc. 2010; 85: 538-550.
22. Baldwin D.S., Reines E.H., Guiton C., Weiller E.: Escitalopram therapy for major depression and anxiety disorders. Ann. Pharmacother. 2007; 41: 1583-1592.
23. FDA/Food and Drug Administration Center for Drug Evaluation and Research (2001) [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf].
24. DeVane C.L.: Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. J. Clin. Psychiatry 2003; 64(supl. 18): 14-19.
25. Demyttenaere K., Albert A., Mesters M. et al.: What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? J. Clin. Psychiatry 2005; 66: 859-863.